Forma Therapeutics and the University of Oxford have entered into a collaboration and license agreement to identify, validate and develop deubiquitinating enzyme (DUB) inhibitors for the treatment of neurodegenerative diseases.
Amneal Pharmaceuticals and Impax Laboratories have completed their business combination to form Amneal Pharmaceuticals.
InDex Pharmaceuticals Holding has developed a novel formulation of its lead drug candidate cobitolimod for oral administration, with targeted delivery to the lower part of the gastrointestinal tract.
Third Rock Ventures has launched Casma Therapeutics with a $58.5m investment to harness the cellular process of autophagy to develop breakthrough therapies.
Janssen Biotech has agreed to acquire US-based BeneVir Biopharm, a biopharmaceutical company focused on developing oncolytic immunotherapies for cancer, in a deal worth $1.04bn.
Vivus has agreed to acquire all product rights for Pancreaze (pancrelipase) Delayed-Release Capsules in the US and Canada held by Janssen Pharmaceuticals, subject to certain closing conditions, including Hart-Scott-Rodino review.
C4X Discovery (C4XD) has entered into a joint research collaboration with e-Therapeutics (ETX) to identify novel mechanisms for the treatment of Parkinson’s Disease (PD).
NX Development (NXDC), a privately-held life sciences company, has announced a merger acquisition under which NXDC became a wholly-owned subsidiary of photonamic GmbH & Co. KG (PHN).
PhoreMost and NeoPhore are set to receiv £1m of funding to develop a novel small-molecule cancer immunotherapy program following award of a Biomedical Catalyst grant in a recent Innovate UK competition.
Corvidia Therapeutics has secured $60m in a Series B funding round to accelerate growth of its ongoing clinical programs, expand scientific and market access capabilities and explore new treatment areas.
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.